ParaZero Unlocks Growth Opportunities After Achieving European Regulatory Compliance for its SafeAir Systems
ParaZero secured EASA compliance for its SafeAir systems. The Company announced last week that its system is integrated with the DJI Matrice 350, DJI Mavic 3T, and DJI Mavic 3E, and has successfully achieved CE Class C5 compliance. This achievement marks a significant advancement in drone safety and regulatory readiness, particularly within the European market.
The CE Class C5 certification is crucial for compliance with the European Union Aviation Safety Agency (EASA) regulations, especially for operators navigating the complex Specific Operations Risk Assessment (SORA) process. By meeting these stringent requirements, ParaZero's SafeAir systems simplify the regulatory pathway for drone operators, enabling them to conduct missions in an urban environment, with greater confidence, efficiency, and safety.
Achieving CE Class C5 compliance ensures that drone operators can now perform operations under the popular Standard Scenario STS-01, which permits drone flights in densely populated urban areas with controlled ground spaces. This reduces the need for extensive documentation and lengthy approval processes, significantly accelerating deployment timelines for commercial and defense drone missions.
ParaZero's SafeAir system is designed to autonomously detect critical failures and deploy a parachute to safely land the drone, minimizing the risk to people and property on the ground. This advanced technology has been integrated into leading drone platforms, providing an added layer of safety for both commercial and defense applications.
With the CE Class C5 certification in place, ParaZero is well-positioned to support drone operators across Europe in meeting regulatory requirements, unlocking new business opportunities in industries such as logistics, infrastructure inspection, emergency response, and defense.
About ParaZero Technologies
ParaZero (Nasdaq: PRZO) is an aerospace company focused on drone safety systems for defense and commercial drones and urban air mobility aircraft. Started in 2014 by a passionate group of aviation professionals and drone industry veterans, ParaZero designs smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond-visual-line-of-sight (BVLOS) as well as for various military applications including Counter UAS. For more information about ParaZero, please visit https://parazero.com/
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed with the SEC on March 21, 2024. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.
Investor Relations Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Is Twist Bioscience Corp. (TWST) Nearing Profitability?
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Micro Cap Composite appreciated 15.65% net-of-fees in the second quarter but underperformed the Russell Microcap Growth Index's 20.92% return. In a highly volatile market led by high-beta and lower-quality stocks, the firm does not expect the fund to align with index performance. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Twist Bioscience Corporation (NASDAQ:TWST). Twist Bioscience Corporation (NASDAQ:TWST) manufactures and distributes synthetic DNA-based products. The one-month return of Twist Bioscience Corporation (NASDAQ:TWST) was -2.17%, and its shares lost 37.34% of their value over the last 52 weeks. On July 25, 2025, Twist Bioscience Corporation (NASDAQ:TWST) stock closed at $35.99 per share, with a market capitalization of $2.16 billion. Conestoga Capital Advisors stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its second quarter 2025 investor letter: "Twist Bioscience Corporation (NASDAQ:TWST) is a rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform that manufactures synthetic DNA by 'writing' it on a silicon chip. TWST leverages their unique technology platform to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development. Conestoga was a shareholder of TWST from 2019 to 2020 and sold due to its market cap exceeding our limit. With the weakness in healthcare, Conestoga is reinvesting. TWST's fundamentals have remained robust, management has been upgraded, and we believe they are nearing profitability." A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug discovery. Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 30 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the first quarter compared to 26 in the previous quarter. In the second quarter of 2025, Twist Bioscience Corporation (NASDAQ:TWST) reported revenue of $92.8 million, reflecting an increase of 23% year-over-year. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Twist Bioscience Corporation (NASDAQ:TWST) and shared the list of best genomics stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
20 minutes ago
- Yahoo
Fly-E Group, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (Nasdaq: FLYE) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on July 22, 2025, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement. To regain compliance with the minimum bid price requirement, the Company's common stock is required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company evidenced a closing bid price of its common stock at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from July 7, 2025 through July 21, 2025. Accordingly, Nasdaq determined that Fly-E has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is now closed. About Fly-E Group, Inc. Fly-E Group, Inc. is an electric vehicle company that is principally engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes and electric under the brand "Fly E-Bike." The Company's commitment is to encourage people to incorporate eco-friendly transportation into their active lifestyles, ultimately contributing towards building a more environmentally friendly future. For more information, please visit the Company's website: Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results, and that the forward-looking statements contained in this press release are subject to the risks set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section under "Risk Factors" of its most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2025, filed with the SEC on July 15, 2025. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. For investor and media inquiries, please contact: Fly-E Group, Relations DepartmentEmail: ir@ Ascent Investor Relations LLCTina XiaoPhone: +1-646-932-7242Email: investors@ in to access your portfolio
